Gossamer Bio, Inc.
Clinical-stage biopharma developing inhaled therapies for rare pulmonary hypertension.
GOSS | NDAQ
Overview
Corporate Details
- ISIN(s):
- US38341P1021
- LEI:
- Country:
- United States of America
- Address:
- 3115 MERRYFIELD ROW, 92121 SAN DIEGO
- Website:
- https://www.gossamerbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics for rare diseases. The company's primary focus is on its lead investigational product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is a novel, inhaled inhibitor of the PDGFRα/β, CSF1R, and c-KIT protein receptors, designed for delivery via a dry powder inhaler. Gossamer Bio aims to advance this potential therapy through clinical development to address unmet needs for patients with these life-threatening conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Gossamer Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gossamer Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gossamer Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
